Abstract/Overview
Invasive cervical cancer (ICC) is common in areas where human immunodeficiency virus (HIV) is also prevalent. Currently, HIV seroprevalence as well as acceptability of HIV testing in ICC patients in Kenya is unknown. The objective of this study was to determine the acceptability of HIV testing among patients with ICC. Women with histologically verified ICC at Kenyatta National Hospital participated in the study. A structured questionnaire was administered to patients who gave informed consent. HIV pre- and posttesting counseling was done. Blood was tested for HIV using enzyme-linked immunosorbent assay. Overall, 11% of ICC patients were HIV seropositive. The acceptance rate of HIV testing was 99%; yet, 5% of the patients did not want to know their HIV results. Patients less than 35 years old were two times more likely to refuse the result of the HIV test (odds ratio [OR] 2.2). Patients who did not want to know their HIV results were three times more likely to be HIV seropositive (OR 3.1). Eighty four percent of the patients were unaware of their HIV seropositive status. The HIV-1 seroprevalence in ICC patients was comparable to the overall seroprevalence in Kenya. ICC patients were interested in HIV testing following pretest counseling. Offering routine HIV testing is recommended in ICC patients.
Bwayoy, G (2024). Acceptability of human immunodeficiency virus testing in patients with invasive cervical cancer in Kenya. Afribary. Retrieved from https://tracking.afribary.com/works/accept-ability-of-human-immunode-ciency-virustesting-in-patients-with-invasivecervical-cancer-in-kenya
Bwayoy, Gichangi "Acceptability of human immunodeficiency virus testing in patients with invasive cervical cancer in Kenya" Afribary. Afribary, 16 Jul. 2024, https://tracking.afribary.com/works/accept-ability-of-human-immunode-ciency-virustesting-in-patients-with-invasivecervical-cancer-in-kenya. Accessed 21 Nov. 2024.
Bwayoy, Gichangi . "Acceptability of human immunodeficiency virus testing in patients with invasive cervical cancer in Kenya". Afribary, Afribary, 16 Jul. 2024. Web. 21 Nov. 2024. < https://tracking.afribary.com/works/accept-ability-of-human-immunode-ciency-virustesting-in-patients-with-invasivecervical-cancer-in-kenya >.
Bwayoy, Gichangi . "Acceptability of human immunodeficiency virus testing in patients with invasive cervical cancer in Kenya" Afribary (2024). Accessed November 21, 2024. https://tracking.afribary.com/works/accept-ability-of-human-immunode-ciency-virustesting-in-patients-with-invasivecervical-cancer-in-kenya